Magro Lara, Arzenton Elena, Leone Roberto, Stano Marilisa Giustina, Vezzaro Michele, Rudolph Annette, Castagna Irene, Moretti Ugo
Section of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Front Pharmacol. 2021 Jan 18;11:622862. doi: 10.3389/fphar.2020.622862. eCollection 2020.
Drug-drug interactions (DDIs) are an important cause of adverse drug reactions (ADRs). In literature most of studies focus only on potential DDIs, while detailed data on serious ADRs associated with DDIs are limited. Our aim is to identify and characterize serious ADRs caused by DDIs using a spontaneous reporting database. All serious ADR reports, not related to vaccines and with a "definite", "probable" or "possible" causality assessment, inserted into the National Pharmacovigilance database from Veneto Region (January 1, 2015 to May 31, 2020) were analyzed. A list of drug pairs was created by selecting the reports containing at least two suspected or concomitant drugs. We verified which drug pairs potentially interacted according to the online version of DRUGDEX system. For each potential DDI we controlled whether the ADR description in the report corresponded to the interaction effect as described in Micromedex. A detailed characterization of all serious reports containing an occurring DDI was performed. In the study period a total of 31,604 reports of suspected ADRs from the Veneto Region were identified, of which 2,195 serious reports (6.9% of all ADR reports) containing at least two suspected or concomitant drugs were analyzed. We identified 1,208 ADR reports with at least one potential DDI (55.0% of 2,195) and 381 reports (17.4% of 2,195 reports) with an occurring ADR associated with a DDI. The median age of patients and the number of contraindicated or major DDIs were significantly higher in reports with an occurring DDI. Warfarin was the most frequently reported interacting drug and the most common ADRs were gastrointestinal or cerebral hemorrhagic events. The proton pump inhibitors/warfarin, followed by platelet aggregation inhibitors/warfarin were the drug-drug combinations most frequently involved in ADRs caused by DDIs. The highest proportion of fatal reports was observed with platelet aggregation inhibitors/warfarin and antidepressants/warfarin. Our findings showed that about one-third of patients exposed to a potential DDI actually experienced a serious ADR. Furthermore, our study confirms that a spontaneous reporting database could be a valuable resource for identifying and characterizing ADRs caused by DDIs and the drugs leading to serious ADRs and deaths.
药物相互作用(DDIs)是药物不良反应(ADRs)的一个重要原因。在文献中,大多数研究仅关注潜在的药物相互作用,而与药物相互作用相关的严重药物不良反应的详细数据有限。我们的目的是使用一个自发报告数据库来识别和描述由药物相互作用引起的严重药物不良反应。对2015年1月1日至2020年5月31日期间录入威尼托地区国家药物警戒数据库的所有严重药物不良反应报告进行了分析,这些报告与疫苗无关,且因果关系评估为“肯定”“很可能”或“可能”。通过筛选包含至少两种可疑或同时使用药物的报告,创建了一份药物对清单。我们根据DRUGDEX系统的在线版本核实了哪些药物对可能相互作用。对于每一种潜在的药物相互作用,我们对照Micromedex中描述的相互作用效应,检查报告中的药物不良反应描述是否与之相符。对所有包含已发生药物相互作用的严重报告进行了详细描述。在研究期间,共识别出威尼托地区31,604份可疑药物不良反应报告,其中分析了2,195份严重报告(占所有药物不良反应报告的6.9%),这些报告包含至少两种可疑或同时使用药物。我们识别出1,208份至少有一个潜在药物相互作用的药物不良反应报告(占2,195份报告的55.0%)以及381份与药物相互作用相关的已发生药物不良反应报告(占2,195份报告的17.4%)。在有已发生药物相互作用的报告中,患者的年龄中位数以及禁忌或主要药物相互作用的数量显著更高。华法林是报告中最常出现的相互作用药物,最常见的药物不良反应是胃肠道或脑出血事件。质子泵抑制剂/华法林,其次是血小板聚集抑制剂/华法林,是药物相互作用引起药物不良反应最常涉及的药物组合。在血小板聚集抑制剂/华法林和抗抑郁药/华法林的报告中观察到最高比例的致命报告。我们的研究结果表明,约三分之一暴露于潜在药物相互作用的患者实际经历了严重药物不良反应。此外,我们的研究证实,自发报告数据库可能是识别和描述由药物相互作用引起的药物不良反应以及导致严重药物不良反应和死亡的药物的宝贵资源。